ArticleEuropean journal of nuclear medicine and molecular imaging2011
Differential diagnosis of solitary pulmonary nodules using ⁹⁹mTc-3P₄-RGD₂ scintigraphy.
Article in European journal of nuclear medicine and molecular imaging, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04504565 (The Efficacy of 99mTc-3PRGD2 SPECT/CT Imaging in the Diagnosis of Lymph Node Metastasis of Esophageal Carcinoma), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Efficacy of 99mTc-3PRGD2 SPECT/CT Imaging in the Diagnosis of Lymph Node Metastasis of Esophageal Carcinoma
Who cites it
26 citing papers in PubMed.
- Advances in Clinical Oncology Research onFrontiers in oncology · 2022Review
- Scintigraphic Imaging of Neovascularization WithFrontiers in oncology · 2021Article
- Observational
- Comparison of [Molecular imaging and biology · 2018Article
- Clinical study ofOncotarget · 2017Article
- Synthesis, Chemical Characterization and Multiscale Biological Evaluation of a Dimeric-cRGD Peptide for Targeted Imaging of αScientific reports · 2017Article
- An Assisted Diagnosis System for Detection of Early Pulmonary Nodule in Computed Tomography Images.Journal of medical systems · 2017Article
- Comparison of biological properties ofNuclear medicine and biology · 2016Article
- Radiolabeled cyclic RGD peptides as radiotracers for tumor imaging.Biophysics reports · 2016Review
- Targeting activated hepatic stellate cells (aHSCs) for liver fibrosis imaging.EJNMMI research · 2015Article
- (18)F-Alfatide II PET/CT in healthy human volunteers and patients with brain metastases.European journal of nuclear medicine and molecular imaging · 2015Article
- Radiolabeled Cyclic RGD Peptide Bioconjugates as Radiotracers Targeting Multiple Integrins.Bioconjugate chemistry · 2015Review
- ⁹⁹mTc-3PRGD₂ SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer.European journal of nuclear medicine and molecular imaging · 2015Article
- (99m)Tc-3P-RGD2 SPECT to monitor early response to bevacizumab therapy in patients with advanced non-small cell lung cancer.International journal of clinical and experimental pathology · 2015Article
- Article
- FITC-conjugated cyclic RGD peptides as fluorescent probes for staining integrin αvβ3/αvβ5 in tumor tissues.Bioconjugate chemistry · 2014Article
- Impact of multiple negative charges on blood clearance and biodistribution characteristics of 99mTc-labeled dimeric cyclic RGD peptides.Bioconjugate chemistry · 2014Article
- 99mTc-3P4-RGD2 scintimammography in the assessment of breast lesions: comparative study with 99mTc-MIBI.PloS one · 2014Article
- Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.Theranostics · 2014Article
- (99m)Tc-Galacto-RGD2: a novel 99mTc-labeled cyclic RGD peptide dimer useful for tumor imaging.Molecular pharmaceutics · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTargeting of integrin α(ν)β(3) with molecular imaging agents offers great potential in early detection and monitoring of tumour angiogenesis. Recently, an RGD (Arg-Gly-Asp) tracer, (99m)Tc-3P(4)-RGD(2), with high affinity to integrin α(ν)β(3) and in vivo tumour uptake was developed. In this study, we evaluate the feasibility of this novel radiotracer in the noninvasive differentiation of solitary pulmonary nodules (SPNs).
methodsTwenty-one patients with SPNs on CT were studied scintigraphically after administration of (99m)Tc-3P(4)-RGD(2) with a dose of 939 ± 118 MBq. Image interpretation using a 5-point scale was performed by one thoracic radiologist for CT and three nuclear medicine radiologists for single photon emission computed tomography (SPECT). Scintigraphic images were also analysed semiquantitatively by calculating tumour to normal tissue ratio (T/N). The "gold standard" was based on the histopathological diagnosis of the surgical samples from all recruited patients. A fraction of the samples were analysed immunohistochemically for integrin α(v)β(3) expression.
resultsAmong the 21 SPNs, 15 (71%) were diagnosed as malignant and 6 (29%) were benign. The mean size for SPNs was 2.2 ± 0.6 cm. The sensitivity and specificity for CT interpretation, SPECT visual and semiquantitative analysis were 80/67%, 100/67% and 100/67%, respectively. All SPNs classified as indeterminate by CT were correctly diagnosed by (99m)Tc-3P(4)-RGD(2) scintigraphy. The empirical receiver-operating characteristic (ROC) areas were 0.811 [95% confidence interval (CI) 58-95%] for CT, 0.833 (95% CI 61-96%) for SPECT and 0.844 (95% CI 62-96%) for T/N ratios, respectively. Immunohistochemistry confirmed α(ν)β(3) expression in malignant and benign nodules with uptake in (99m)Tc-3P(4)-RGD(2) scintigraphy.
conclusionIn this first-in-human study, we demonstrated the feasibility of using (99m)Tc-3P(4)-RGD(2) scintigraphy in differentiating SPNs. This procedure appears to be highly sensitive in detection of malignant SPNs. SPECT visual analysis seems to be sufficient for characterization of SPNs.
Indexed as
Identifiers
21874323What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.